Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;63(10):e281-e284.
doi: 10.1093/rheumatology/keae182.

TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients

Huong D Nguyen  1 , Fabienne Jouen  2   3 , Benoit Déchelotte  2   3 , Nadège Cordel  2   4 , Cyril Gitiaux  5   6 , Christine Bodemer  7 , Pierre Quartier  5   8 , Alexandre Belot  9 , Kathryn O'Brien  1 , Dario Cancemi  1 , Isabelle Melki  10 , Nicole Fabien  11 , Sarah Tansley  12   13 , Olivier Boyer  2   3 , Lucy R Wedderburn  1   14   15 , Brigitte Bader-Meunier  5   8 ; UK JDM Cohort and Biomarker Study
Collaborators, Affiliations

TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patients

Huong D Nguyen et al. Rheumatology (Oxford). .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Detection of anti-TIF1γ auto-antibodies and demographic association in patients with JDM. Anti-TIF1γ auto-antibodies were measured by lineblot or immunoprecipitation. Anti-TIF1γ isotypes including IgG1, IgG2, IgG3 and IgG4 were measured using the multiplex ALBIA assay in both cohorts. (A) Diverse combination of anti-TIF1γ isotypes detected in JDM patients from French and UK cohorts. (B) Anti-TIF1γ IgG2 positive patients were analysed according to ethnicity: anti-TIF1γ IgG2 is more prevalent in non-Caucasian patients
See this image and copyright information in PMC

References

    1. Papadopoulou C, Chew C, Wilkinson MGL, McCann L, Wedderburn LR. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat Rev Rheumatol 2023;19:343–62. - PMC - PubMed
    1. Tansley SL, Simou S, Shaddick G et al. Autoantibodies in juvenile-onset myositis: heir diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun 2017;84:55–64. - PMC - PubMed
    1. Yasin SA, Schutz PW, Deakin CT et al.; UK Juvenile Dermatomyositis Research Group (UK and Ireland). Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol Appl Neurobiol 2019;45:495–512. - PMC - PubMed
    1. Cordel N, Dechelotte B, Jouen F et al. Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study. Rheumatology (Oxford) 2022;62:1711–5. - PubMed
    1. Aussy A, Fréret M, Gallay L et al.; OncoMyositis Study Group. The IgG2 isotype of anti-transcription intermediary factor 1γ autoantibodies is a biomarker of cancer and mortality in adult dermatomyositis. Arthritis Rheumatol 2019;71:1360–70. - PubMed